BiotechTube
myBiometry

myBiometry

San Francisco, United States· Est.
mybiometry.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

myBiometry is a private, pre-revenue US digital health startup founded in 2019, building an integrated platform for asthma management. The company's solution centers on a patented at-home FeNO sensor and a companion app that aggregates biomarker, clinical, and environmental data to generate predictive risk models and deliver automated, guideline-based coaching. Led by a seasoned team with medical device and diagnostics expertise, myBiometry aims to shift asthma care from reactive symptom management to proactive, biologically-informed prevention, though its technology is still in development and not yet FDA-cleared.

Asthma

Technology Platform

Integrated digital health platform combining a patented at-home FeNO biomarker sensor, a mobile app for data aggregation, and an AI/ML prediction engine to generate personalized risk models and deliver automated coaching for chronic disease management.

Opportunities

The large and costly asthma patient population creates a significant addressable market for solutions that reduce exacerbations and hospital visits.
The shift towards value-based care and remote patient monitoring provides a favorable reimbursement and adoption tailwind.
The platform's core technology could be adapted to other chronic conditions with measurable biomarkers, enabling future expansion.

Risk Factors

The company faces significant regulatory risk as its unapproved sensor/software combination device must undergo FDA review.
Clinical adoption risk is high, requiring proof of improved outcomes and integration into clinical workflows.
Competition from other digital health tools and the challenge of manufacturing a reliable, low-cost sensor at scale present additional execution risks.

Competitive Landscape

myBiometry competes in the digital asthma management space, which includes symptom-tracking apps (e.g., Propeller Health) and traditional, clinic-based FeNO device manufacturers (e.g., Circassia, NIOX). Its key differentiation is the combination of a proprietary at-home FeNO sensor with predictive AI analytics, aiming to provide a more biologically-rooted and proactive solution than symptom-only apps.

More companies in Digital Health & Biotech SaaS →More companies in United States →